Brief: Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall Of Taro-Zoledronic Acid Injection, 5 Mg/100 Ml, 100 Ml Vial Due To Particulate Matter Over Specified Requirements

Taro Pharmaceutical Industries

11/08/2022 23:25

Aug 11 (Reuters) - Taro Pharmaceutical Industries Ltd
 TARO.N :
    * TARO PHARMACEUTICALS INC. ISSUES VOLUNTARY TYPE I RECALL
OF
TARO-ZOLEDRONIC ACID INJECTION, 5 MG/100 ML, 100 ML VIAL DUE TO
PARTICULATE MATTER OVER SPECIFIED REQUIREMENTS
    * TARO PHARMACEUTICAL INDUSTRIES LTD - REASON FOR RECALL IS
THAT
PRODUCT FROM LOTS MAY CONTAIN PARTICULATE MATTER OVER SPECIFIED
REQUIREMENTS
    * TARO PHARMACEUTICAL INDUSTRIES - PRESENCE OF FOREIGN
PARTICULATE
MATTER IN VIALS OF AFFECTED LOTS COULD POTENTIALLY CAUSE
UNINTENDED ADVERSE EVENTS
    * TARO PHARMACEUTICAL INDUSTRIES LTD - HAS RECEIVED NO
REPORTS OF
SERIOUS ADVERSE EVENTS ASSOCIATED WITH PRODUCT

Source text for Eikon:  ID:nBw61bvxja 
Further company coverage:  TARO.N 

 ((Reuters.Briefs@thomsonreuters.com;))